Navigation Links
NCH partners with Silicon Valley to market high-end diagnostic and medical research software
Date:10/30/2012

The latest significant biomedical informatics technology is not coming from the biotech industry or a university. In fact, it's coming from a children's hospital.

Nationwide Children's Hospital in Columbus, Ohio, and Transformatix Technologies, Inc., in Davis, California, have partnered to create BioLinQ, a new biomedical informatics company designed to supply advanced software solutions for disease diagnosis and medical research.

"Years of development at Nationwide Children's Hospital funded in part by the National Institutes of Health have laid the foundation for very mature, high-end solutions in digital pathology, biospecimen analysis and biorepository management," says Ken Murray, founder and CEO, Transformatix Technologies, Inc. "With the growth of molecular technology and the advent of personalized medicine, BioLinQ is poised to have a significant impact upon the diagnostic and research capabilities in hospitals, academic research centers and the pharmaceutical industry."

The vision of the late Stephen J. Qualman, MD, who developed the Biopathology Center at Nationwide Children's, provided the foundation to advance the hospital's capabilities in the field of pathology, as well as biobanking and sophisticated digital analysis. Software solutions developed at Nationwide Children's answer the needs for highly defined biospecimen analysis, workflow management, long-distance collaboration and efficient management of laboratory and biorepository functions.

"We are seeing, with the implementation of our software, the optimization of the scientific review process for translational research. The solutions also provide visualization into the multiple dynamics of clinical trial data to aid in clinical study design," explains Dave Billiter, director, Informatics, The Research Institute at Nationwide Children's Hospital. "For example, we have a cancer consortium which called for patients to receive rapid review in order to qualif
'/>"/>

Contact: Erin Pope
Erin.Pope@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Immune system fighters speak in patterns of proteins, prefer squishy partners
2. British Ecological Society partners with Wiley open access journal Ecology and Evolution
3. DARPA director: Revolutionary weapons require strong S&T partnerships
4. Partnership enhances biology teaching at California community colleges
5. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
6. MU celebrates $5 million partnership for advancing biomedical discoveries
7. BGI partners with the University of Birmingham
8. Sandia seeks commercial partners for revolutionary SpinDx medical diagnostic tool
9. F1000 Research partners with figshare to provide smart ways of accessing data
10. Royal Astronomical Society and Oxford University Press partnership announced
11. Grants add to Northwestern-Qatar partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
(Date:5/17/2013)... the interaction of a group of proteins in the ... identified a new target that could increase cell survival. ... School of Biochemistry and published in the EMBO ... eventually lead to new therapies for stroke and other ... by the team which identified a protein, known as ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2SUMO wrestling cells reveal new protective mechanism target for stroke 2
... 10, 2009)Attempts to treat critical limb ischemia in ... are still thwarted by restenosis (the re-narrowing of ... stenting), the need for repeat treatments and the ... death (gangrene) and amputation. Interventional radiologists have been ...
... Detects Faces in Motion, Matches with Watch-list ... Lithuania, March 9 Neurotechnology, a provider ... the availability of VeriLook Surveillance SDK, a ... using live video streams from high-resolution digital ...
... be tough, but scientists have found a Yellowstone National ... simple one-celled algae called Cyanidioschyzon -- thrives ... occurs naturally around hot springs, said Tim McDermott, professor ... at Montana State University. Cyanidioschyzon could ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3Montana State team finds Yellowstone alga that detoxifies arsenic 2Montana State team finds Yellowstone alga that detoxifies arsenic 3
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... May 21, 2013  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... of serious infectious diseases, announced today that Jeffrey ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, ... the Grand Hyatt Hotel. Mr. Riley is scheduled to present ... of Synthetic Biologics, presentation can be accessed by logging onto ...
(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... BOULDER, Colo., and IPSWICH, Mass., July 27, ... Biolabs, Inc. (NEB) announce today that they ... whereby SomaLogic will provide specific SOMAmers as ... and future NEB nucleic acid amplification and ...
... July 27, 2011 Cadence Pharmaceuticals, Inc. (NASDAQ: ... and commercializing proprietary products principally for use in the hospital ... ended June 30, 2011 financial results on Wednesday, August 3, ... call and live webcast to discuss the financial results on ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... registration trial of KRX-0401 (perifosine) for the treatment of ... over 430 randomized patients, is being conducted pursuant to ... Drug Administration (FDA) and with Fast-Track Designation.  Perifosine is ...
Cached Biology Technology:Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 4Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study 5